receive**d** Central sax center

### Procter & Gamble - I.P. Division

JAN 2 7 2004

#### IMPORTANT CONFIDENTIALITY NOTICE

The documents accompanying this telecopy transmission contain confidential information belonging to the sender which is legally protected. The information is intended only for the use of the individual or entity named below. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this telecopied information is strictly prohibited. If you have received this telecopy in error, please immediately notify us by telephone (collect) to arrange for return of the telecopied document to us.

### FACSIMILE TRANSMITTAL SHEET AND CERTIFICATE OF TRANSMISSION UNDER 37 CFR 1.8

TO: Central Number (IDS) - United States Patent and Trademark Office

Fax No. 703-872-9306

Phone No.

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office on 27, 2004, to the above-identified facsimile number.

FROM: Linda R. Schroer\_ (Typed or printed name of person signing Certificate)

Fax No. 513-622-3300

Phone No. 513-622-2859

Listed below are the item(s) being submitted with this Certificate of Transmission:\*\*

1) Information Disclosure Statement (3pgs/2 copies)

Copy of PTO 1449 from Parent Case (1pg/ 1 copy)

3)

4)

5)

Comments:

Number of Pages Including this Page: 8

Inventor(s): Adam Wiesalw Mazur et al.

S.N.:

10/612,104

Filed:

07/02/2003

Case:

7490MC

\*\*Note: Each paper must have its own certificate of transmission, OR this certificate must identify each submitted paper.



### P&G Case 7490MC

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

D TRADEMARK OFFICE RECEIVED

CENTRAL PAX CENTER

In the application of :
Adam Wieslaw Mazur et al. : Confirmation No. 3400
Serial No. 10/612,104 : Group Art Unit 1654

Group Art Unit 1654

Examiner

JAN 2 7 2004

Filed 07/02/2003

Melanocortin Receptor Ligands

### INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, record is being made on the attached Form PTO/SB08 of documents which the Patent Office may wish to consider in connection with examination of the above-identified patent application. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case. As provided in §1.97(g), no representation is made or intended that a thorough art search was made. As provided in 37 C.F.R. §1.97(h), this Information Disclosure Statement does not constitute an admission of any kind, and specifically is not an admission that the documents listed on attached form PTO/SB08 are, or are considered to be, material to the patentability of the above-identified patent application, as defined in 37 C.F.R. §1.56(b).

1. [] 37 C.F.R. \$1.97(b)(1) - U.S. Direct (use when filing IDS with nonprovisional patent application, or with Request for Continued Examination (RCE); or within 3 months of filing a nonprovisional patent application)

This information disclosure statement, submitted under 37 C.F.R. §1.97(b)(1), is being filed with the patent application, with a Request for Continued Examination or within three months of the filing date of a national application. Therefore, no fee is believed to be due.

### 2. [X] 37 C.F.R. §1.97(b)(3) - (use when filing IDS more than 3 months after filing a nonprovisional patent application, but prior to receipt of first Office Action)

This information disclosure statement is being submitted under 37 C.F.R. §1.97(b)(3). Applicants have not received an Office Action on the merits in the present application. Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter (or a fee transmittal form) is enclosed to facilitate charging of the fee, if necessary.

## 3. [] 37 C.F.R. §1.97(b)(4) - (use when filing IDS prior to receipt of first Office Action after the filing of a Request for Continued Examination (RCE) under §1.114)

This information disclosure statement is being submitted under 37 C.F.R. §1.97(b)(4). Applicants have not received a first Office Action after filing a Request For Continued Examination (RCE). Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter (or a fee transmittal form) is enclosed to facilitate charging of the fee, if necessary.

# 4. [] 37 C.F.R. \$1.97(c) with fee payment - (use when filing IDS after receipt of first Office Action, and before receipt of Final Office Action, Notice of Allowance, or an action that otherwise closes prosecution)

This information disclosure statement is being submitted under 37 C.F.R. §1.97(c). Applicant(s) have not received a final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311, or an action that otherwise closes prosecution in the application (e.g., Ex parte Quayle) as of the date of this submission. Applicant(s) elect to pay the fee set forth in 37 C.F.R. §1.17(p). Please charge the fee set forth in 37 C.F.R. §1.17(p) to Deposit Account Number 16-2480 in the name of The Procter & Gamble Company. A duplicate copy of this letter (or a fee transmittal form) is enclosed to facilitate the charging of the fee.

### ADDITIONAL ITEMS TO BE NOTED BY THE EXAMINER:

[] (1) (For use with applications filed prior to or on June 30, 2003.) Copies of the cited documents are enclosed.

[] (2) (For use with applications filed after June 30, 2003.) In accordance with 37
C.F.R. §1.98(a)(2), Applicants are submitting copies of foreign patent documents and non-
patent literature.
O'R
[X] (3) All of the cited references were previously cited by or submitted to the USPTO in
prior application Case No. 7490M, U.S. Patent Application Serial No. 09/537,789, filed
03/29/2000; U.S. Patent No. 6,613,874, issued 09/02/2003. A copy of the PTO 1449 is
attached, showing cited references. Applicants claim priority to said application under 35
U.S.C. §120. Accordingly, copies of previously submitted references are not provided with this
Statement, pursuant to 37 C.F.R. §1.98(d). It is respectfully requested that the cited documents
be carefully considered by the Examiner and made of record in this case.
OR
F7
and considered in parent application U.S. Patent Application Serial No, filed
Applicant(s) claim priority to said application under 35 U.S.C. §120. Accordingly,
copies of previously submitted references are not provided with this Statement, pursuant to 37
C.F.R. §1.98(d). Copies of references not previously submitted are enclosed. It is respectfully
requested that the cited documents be carefully considered by the Examiner and made of record
in this case.
[] (5) Pursuant to 37 C.F.R. §1.98(c), a concise explanation of the relevance of each cited
reference that is not in the English language is provided.
· · · · · · · · · · · · · · · · · · ·
(6) Applicants also respectfully request the Examiner to consider and make of record
the co-pending applications listed on the attached page.
the co-pending applications used on the attached page.
Additional information is attached.
(Respectfully subplices,
Richard S. Echler, Sr.
Date: January 27, 2004 Attorney or Agent for Applicant(s)
Customer No. 27752 Registration No. 41,006
IDS.doc) (14st Revised 10/10/03) (513)622-1973

Sheet 1 of 1

FORM PTO-1449

LIST OF DOCUMENTS CITED BY APPLICANTS (Use several sheets if necessary)	ATTY, DOCKET NO. 7490M	SERIAL NO. 09/537,789
(Use saveral should it housedary)	APPLICANT A. W. Mazur, et al.	
	FILING DATE March 29, 2000	GROUP 1646

### U. S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	5,462,927	10/31/95	Moreau et al	514	17	
	5,569,741	10/29/96	Coy et al	530	311	
	5,770,380	06/23/98	Hamilton et al	435	7.1	

### FOREIGN PATENT DOCUMENTS

	DOCUMENT	DATE	COUNTRY	CLASS	SUB	TRANSLATION YES NO
	NUMBER 0 292 291	08/10/94	EPO	C07K		
	0 309 297	11/09/94	EPO	C07K		
	0 499 266	02/14/92	EPO	C07K		
<del></del>	0 427 458	11/01/90	EPO	A61K		
	0 528 312	08/08/92	EPO	C07K		
	0 547 317	10/08/92	EPO	Ç07K		
	0 552 417	10/08/92	EPO	C07K		
	0 632 052	06/01/94	EPO	C07K		
	0 714 909	05/06/96	EPO	C07K		
	0 815 870	01/07/98	EPO	A61K		
	0 967 222	12/29/99	EPO	C07K		
	WO 94/02163	07/27/93	PCT	A61K		
	WO 96/17617	12/07/95	PCT	A61K		
	WO 96/34012	04/25/96	PCT	C07K		
	WO 97/08203	08/26/97	PCT	C07K		
	WO 97/47317	06/11/97	PCT	A61K		
	WO 98/22128	11/18/97	PCT	A61K		
	WO 98/27113	12/17/97	PCT	C07K		
	WO 98/37097	02/16/98	PCT	C07K		
	WO 00/35952	12/14/99	PCT	C07K		

### OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		DATE CONSIDERED
EXAMINER		DATE CONSIDERED
EXAMINEA: Initial line through citation to applicant.	al if r	eference considered, whether or not citation is in conformance with MPEP 609; draw not in conformance and not considered. Include copy of this form with next communication

Patent and Trademark Office - U.S. DEPARTMENT OF COMMERCE